ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 27 of 158 for:    Recruiting, Not yet recruiting, Available Studies | "Eczema"

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable (BREEZE-AD4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03428100
Recruitment Status : Recruiting
First Posted : February 9, 2018
Last Update Posted : December 4, 2018
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine or are intolerant to, or have contraindication to cyclosporine.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: Baricitinib Drug: Placebo Drug: Topical corticosteroid Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
Actual Study Start Date : May 15, 2018
Estimated Primary Completion Date : June 20, 2019
Estimated Study Completion Date : March 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema Steroids

Arm Intervention/treatment
Experimental: Baricitinib High Dose
Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
Drug: Baricitinib
Administered orally.
Other Name: LY3009104

Drug: Placebo
Administered orally.

Drug: Topical corticosteroid
Administered topically.

Experimental: Baricitinib Mid Dose
Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally in combination with topical corticosteroids to maintain the blind.
Drug: Baricitinib
Administered orally.
Other Name: LY3009104

Drug: Placebo
Administered orally.

Drug: Topical corticosteroid
Administered topically.

Experimental: Baricitinib Low Dose
Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally in combination with topical corticosteroids to maintain the blind.
Drug: Baricitinib
Administered orally.
Other Name: LY3009104

Drug: Placebo
Administered orally.

Drug: Topical corticosteroid
Administered topically.

Placebo Comparator: Placebo
Placebo administered orally in combination with topical corticosteroids.
Drug: Placebo
Administered orally.

Drug: Topical corticosteroid
Administered topically.




Primary Outcome Measures :
  1. Proportion of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 with a ≥ 2 Point Improvement (High or Mid Dose) [ Time Frame: 16 Weeks ]
    Proportion of participants achieving IGA of 0 or 1 with a ≥ 2 point improvement


Secondary Outcome Measures :
  1. Proportion of Participants Achieving IGA of 0 or 1 with a ≥ 2 Point Improvement (Low Dose) [ Time Frame: 16 Weeks ]
    Proportion of participants achieving IGA of 0 or 1 with a ≥ 2 point improvement

  2. Proportion of Participants Achieving Eczema Area and Severity Index 75 (EASI75) [ Time Frame: 16 Weeks ]
    Proportion of participants achieving EASI75

  3. Proportion of Participants Achieving EASI90 [ Time Frame: 16 Weeks ]
    Proportion of participants achieving EASI90

  4. Percent Change from Baseline in EASI Score [ Time Frame: Baseline, 16 Weeks ]
    Percent change from baseline in EASI score

  5. Proportion of Participants Achieving SCORing Atopic Dermatitis (SCORAD75) [ Time Frame: 16 Weeks ]
    Proportion of participants achieving SCORAD75

  6. Proportion of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS) [ Time Frame: 16 Weeks ]
    Proportion of participants achieving a 4-point improvement in Itch NRS

  7. Change from Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS) [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in the score of Item 2 of the ADSS

  8. Change from Baseline in Skin Pain NRS [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in skin pain NRS

  9. Proportion of Participants Achieving EASI50 [ Time Frame: 16 Weeks ]
    Proportion of participants achieving EASI50

  10. Proportion of Participants Achieving IGA of 0 [ Time Frame: 16 Weeks ]
    Proportion of participants achieving IGA of 0

  11. Change from Baseline in SCORAD [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in SCORAD

  12. Proportion of Participants Achieving SCORAD90 [ Time Frame: 16 Weeks ]
    Proportion of participants achieving SCORAD90

  13. Change from Baseline in Body Surface Area (BSA) Affected [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in BSA affected

  14. Proportion of Participants Developing Skin Infections Requiring Antibiotic Treatment [ Time Frame: 16 Weeks ]
    Proportion of participants developing skin infections requiring antibiotic treatment

  15. Mean Number of Days without Topical Corticosteroids (TCS) Use [ Time Frame: 16 Weeks ]
    Mean number of days without TCS use

  16. Mean Gram Quantity of TCS Use (Tube Weights) [ Time Frame: 16 Weeks ]
    Mean number of days of TCS use (tube weights)

  17. Percent Change from Baseline in Itch NRS [ Time Frame: Baseline, 16 Weeks ]
    Percent change from baseline in Itch NRS

  18. Change from Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM) [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in the total score of the POEM

  19. Change from Baseline in the Patient Global Assessment of Severity -Atopic Dermatitis (PGI-S-AD) Score [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in the PGI-S-AD score

  20. Change from Baseline on the Hospital Anxiety Depression Scale (HADS) [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in the HADS

  21. Change from Baseline in the Dermatology Life Quality Index (DLQI) [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in the DLQI

  22. Change from Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline on the WPAI-AD questionnaire

  23. Change from Baseline in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Score [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in the EQ-5D-5L score



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have been diagnosed with moderate to severe Atopic Eczema (Atopic Dermatitis) for at least 12 months.
  • Have had inadequate response to existing topical (applied to the skin) medications within 6 months preceding screening.
  • Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).
  • Agree to use emollients daily.
  • Have a medical contraindication to cyclosporine, or had intolerance and/or unacceptable toxicity or inadequate response to cyclosporine in the past.

Exclusion Criteria:

  • Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.
  • A history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.
  • Participants who are currently experiencing a skin infection that requires treatment, or are currently being treated, with topical or systemic antibiotics.
  • Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
  • Have been treated with the following therapies:

    • Monoclonal antibody for less than 5 half-lives prior to randomization.
    • Received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks prior to randomization.
    • Received oral corticosteroids within 4 weeks prior to randomization or parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.
    • Have had an intra-articular corticosteroid injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization.
  • Have high blood pressure characterized by a repeated systolic blood pressure >160 millimeters of mercury (mm Hg) or diastolic blood pressure >100 mm Hg.
  • Have had major surgery within the past eight weeks or are planning major surgery during the study.
  • Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.
  • Have a history of recurrent (≥ 2) VTE or are considered at high risk of VTE as deemed by the investigator.
  • Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
  • Have a current or recent and/or clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.
  • Have specific laboratory abnormalities.
  • Have received certain treatments that are contraindicated.
  • Pregnant or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03428100


Contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Clinicaltrials.gov@lilly.com

  Show 105 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Incyte Corporation
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Additional Information:
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT03428100     History of Changes
Other Study ID Numbers: 16841
I4V-MC-JAIN ( Other Identifier: Eli Lilly and Company )
2017-004574-34 ( EudraCT Number )
First Posted: February 9, 2018    Key Record Dates
Last Update Posted: December 4, 2018
Last Verified: December 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Eli Lilly and Company:
eczema
atopic eczema

Additional relevant MeSH terms:
Eczema
Dermatitis
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Cyclosporins
Cyclosporine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors